HIV treatment interruption following Stem cell transplantation
Research type
Research Study
Full title
HIV treatment interruption following Stem cell transplantation with CCR5 negative donor cells for haematological malignancy\n
IRAS ID
215514
Contact name
Ravindra Gupta
Contact email
Sponsor organisation
University College London Hospitals NHS Foundation Trust
Clinicaltrials.gov Identifier
BRC-RCF245/RG/2016, BRC-RCF245/RG/2016
Duration of Study in the UK
4 years, 11 months, 31 days
Research summary
HIV-1 is a chronic disease and lifelong antiretroviral therapy (ART) can be complex and expensive. The annual costs of ART have been estimated to rival those of asthma treatment, at around one billion pounds a year. Cure of HIV would represent huge cost savings on lifelong antiviral medication, as well as avoiding complications from antivirals such as raised cholesterol , kidney effects impairment and bone thinning.\n
REC name
South West - Central Bristol Research Ethics Committee
REC reference
17/SW/0021
Date of REC Opinion
29 Mar 2017
REC opinion
Further Information Favourable Opinion